Aikili Biosystems Inc

Cambridge, MA · Medtech · Private

Automated diagnostic platform with disposable cartridge and deep learning algorithms for same-day breast cancer diagnosis and receptor subtyping from fine needle aspirates

Grants
$1.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Rapid Breast Cancer Diagnosis in Low and Middle Income Countries$400,000
Federal grantDepartment of Health and Human Services · Phase I · Rapid Breast Cancer Diagnosis in Low and Middle Income Countries$400,000
Federal grantDepartment of Health and Human Services · Phase I · Automated molecular diagnosis on fine needle aspirates (FNA)$400,000
Federal grantDepartment of Health and Human Services · Phase I · Automated molecular diagnosis on fine needle aspirates (FNA)$400,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2193SPOC PROTEOMICS INC.——
2194GLYCOMIRA, LLC——
2195Mozaic Medical Inc—$225K
2196Aikili Biosystems Inc——
2197NEOCHORD INC—$63M
2198Nortis, Inc.—$11M
2199Biorasis——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Systems And Methods For Artifical Intelligence Based Cell Analysisapplication
  • Systems And Methods For Artificial Intelligence Based Cell Analysisapplication
  • Systems And Methods For Artifical Intelligence Based Cell Analysisapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.